Aclaris Therapeutics, Inc. 8AT.F Stock
Aclaris Therapeutics, Inc. Price Chart
Aclaris Therapeutics, Inc. 8AT.F Financial and Trading Overview
| Aclaris Therapeutics, Inc. stock price | 1.11 EUR |
| Previous Close | 11.85 EUR |
| Open | 11.85 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 11.85 - 11.85 EUR |
| 52 Week Range | 11.29 - 17.99 EUR |
| Volume | 20 EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 837.2M EUR |
| Beta (5Y Monthly) | 0.528169 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.18 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.8 EUR |
8AT.F Valuation Measures
| Enterprise Value | 668.97M EUR |
| Trailing P/E | N/A |
| Forward P/E | -8.113013 |
| PEG Ratio (5 yr expected) | -0.15 |
| Price/Sales (ttm) | 27.15793 |
| Price/Book (mrq) | 4.5020905 |
| Enterprise Value/Revenue | 21.701 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Aclaris Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.528169 |
| 52-Week Change | -15.028% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 17.99 EUR |
| 52 Week Low | 11.29 EUR |
| 50-Day Moving Average | 11.85 EUR |
| 200-Day Moving Average | 13.9 EUR |
8AT.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 70.68M |
| Float | 56.44M |
| Short Ratio | N/A |
| % Held by Insiders | 2.50% |
| % Held by Institutions | 97.74% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -310.65% |
| Gross Margin | -202.33% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.23% |
| Return on Equity (ttm) | -53.93% |
Income Statement
| Revenue (ttm) | 30.83M EUR |
| Revenue Per Share (ttm) | 0.46 EUR |
| Quarterly Revenue Growth (yoy) | 74.00% |
| Gross Profit (ttm) | -60021000 EUR |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -96279000 EUR |
| Diluted EPS (ttm) | -1.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 170.8M EUR |
| Total Cash Per Share (mrq) | 2.42 EUR |
| Total Debt (mrq) | 2.57M EUR |
| Total Debt/Equity (mrq) | 1.46 EUR |
| Current Ratio (mrq) | 10.098 |
| Book Value Per Share (mrq) | 2.631 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72951000 EUR |
| Levered Free Cash Flow (ttm) | -41215124 EUR |
Profile of Aclaris Therapeutics, Inc.
| Country | Germany |
| State | PA |
| City | Wayne |
| Address | 640 Lee Road |
| ZIP | 19087 |
| Phone | 484 324 7933 |
| Website | https://www.aclaristx.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 100 |
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment offers laboratory services. The company develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. It develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an oral MK2 inhibitor for the treatment of pancreatic and metastatic breast cancer. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Q&A For Aclaris Therapeutics, Inc. Stock
What is a current 8AT.F stock price?
Aclaris Therapeutics, Inc. 8AT.F stock price today per share is 1.11 EUR.
How to purchase Aclaris Therapeutics, Inc. stock?
You can buy 8AT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aclaris Therapeutics, Inc.?
The stock symbol or ticker of Aclaris Therapeutics, Inc. is 8AT.F.
Which industry does the Aclaris Therapeutics, Inc. company belong to?
The Aclaris Therapeutics, Inc. industry is Diagnostics & Research.
How many shares does Aclaris Therapeutics, Inc. have in circulation?
The max supply of Aclaris Therapeutics, Inc. shares is 72.34M.
What is Aclaris Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Aclaris Therapeutics, Inc. PE Ratio is now.
What was Aclaris Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Aclaris Therapeutics, Inc. EPS is -1.18 EUR over the trailing 12 months.
Which sector does the Aclaris Therapeutics, Inc. company belong to?
The Aclaris Therapeutics, Inc. sector is Healthcare.